Screener
Monopar Therapeutics MNPR Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Monopar Therapeutics’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 2:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-016982
| Line item | March 31, 2026 | December 31, 2025* |
|---|---|---|
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable, accrued expenses and other current liabilities | $2,457,748 | $2,735,236 |
| Total current liabilities | 2,457,748 | 2,735,236 |
| Non-current operating lease liability | 131,565 | 154,920 |
| Total liabilities | 2,589,313 | 2,890,156 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: |
Document
FAQ
- What is Monopar Therapeutics's total current liabilities?
- Monopar Therapeutics (MNPR) reported total current liabilities of $2.46M in Q1 2026.
- What is the long-term trend for Monopar Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), Monopar Therapeutics's total current liabilities has grown at a 18.4% compound annual growth rate (CAGR), from $1.18M to $2.74M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Monopar Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude